GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Due to unfavorable lifestyle habits (unhealthy diet and tobacco abuse) the incidence of gastroesophageal reflux disease (GERD) in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers (i)...

Full description

Saved in:
Bibliographic Details
Main Authors: Romana Illig, Eckhard Klieser, Tobias Kiesslich, Daniel Neureiter
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2013/643084
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566220910493696
author Romana Illig
Eckhard Klieser
Tobias Kiesslich
Daniel Neureiter
author_facet Romana Illig
Eckhard Klieser
Tobias Kiesslich
Daniel Neureiter
author_sort Romana Illig
collection DOAJ
description Due to unfavorable lifestyle habits (unhealthy diet and tobacco abuse) the incidence of gastroesophageal reflux disease (GERD) in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers (i) providing an appropriate screening method identifying the presence of the disease, (ii) estimating the risk of evolving cancer, that is, the progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC), (iii) predicting the response to therapy, and (iv) indicating an overall survival—prognosis for EAC patients. Based on histomorphological findings, detailed screening and therapeutic guidelines have been elaborated, although epidemiological studies could not support the postulated increasing progression rates of GERD to BE and EAC. Additionally, proposed predictive and prognostic markers are rather heterogeneous by nature, lack substantial proofs, and currently do not allow stratification of GERD patients for progression, outcome, and therapeutic effectiveness in clinical practice. The aim of this paper is to discuss the current knowledge regarding the GERD-BE-EAC sequence mainly focusing on the disputable and ambiguous status of proposed biomarkers to identify promising and reliable markers in order to provide more detailed insights into pathophysiological mechanisms and thus to improve prognostic and predictive therapeutic approaches.
format Article
id doaj-art-8b9aa3d9fe7c4978bc34485b6b7054d7
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-8b9aa3d9fe7c4978bc34485b6b7054d72025-02-03T01:04:49ZengWileyGastroenterology Research and Practice1687-61211687-630X2013-01-01201310.1155/2013/643084643084GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?Romana Illig0Eckhard Klieser1Tobias Kiesslich2Daniel Neureiter3Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, AustriaInstitute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, AustriaInstitute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, AustriaInstitute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Muellner HauptstraBe 48, 5020 Salzburg, AustriaDue to unfavorable lifestyle habits (unhealthy diet and tobacco abuse) the incidence of gastroesophageal reflux disease (GERD) in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers (i) providing an appropriate screening method identifying the presence of the disease, (ii) estimating the risk of evolving cancer, that is, the progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC), (iii) predicting the response to therapy, and (iv) indicating an overall survival—prognosis for EAC patients. Based on histomorphological findings, detailed screening and therapeutic guidelines have been elaborated, although epidemiological studies could not support the postulated increasing progression rates of GERD to BE and EAC. Additionally, proposed predictive and prognostic markers are rather heterogeneous by nature, lack substantial proofs, and currently do not allow stratification of GERD patients for progression, outcome, and therapeutic effectiveness in clinical practice. The aim of this paper is to discuss the current knowledge regarding the GERD-BE-EAC sequence mainly focusing on the disputable and ambiguous status of proposed biomarkers to identify promising and reliable markers in order to provide more detailed insights into pathophysiological mechanisms and thus to improve prognostic and predictive therapeutic approaches.http://dx.doi.org/10.1155/2013/643084
spellingShingle Romana Illig
Eckhard Klieser
Tobias Kiesslich
Daniel Neureiter
GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
Gastroenterology Research and Practice
title GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
title_full GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
title_fullStr GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
title_full_unstemmed GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
title_short GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
title_sort gerd barrett adenocarcinoma do we have suitable prognostic and predictive molecular markers
url http://dx.doi.org/10.1155/2013/643084
work_keys_str_mv AT romanaillig gerdbarrettadenocarcinomadowehavesuitableprognosticandpredictivemolecularmarkers
AT eckhardklieser gerdbarrettadenocarcinomadowehavesuitableprognosticandpredictivemolecularmarkers
AT tobiaskiesslich gerdbarrettadenocarcinomadowehavesuitableprognosticandpredictivemolecularmarkers
AT danielneureiter gerdbarrettadenocarcinomadowehavesuitableprognosticandpredictivemolecularmarkers